Literature DB >> 16263114

The N-terminal cleavage of cellular prion protein in the human brain.

Isabelle Laffont-Proust1, Baptiste A Faucheux, Raymonde Hässig, Véronique Sazdovitch, Stéphanie Simon, Jacques Grassi, Jean-Jacques Hauw, Kenneth L Moya, Stéphane Haïk.   

Abstract

Human brain cellular prion protein (PrP(c)) is cleaved within its highly conserved domain at amino acid 110/111/112. This cleavage generates a highly stable C-terminal fragment (C1). We examined the relative abundance of holo- and truncated PrP(c) in human cerebral cortex and we found important inter-individual variations in the proportion of C1. Neither age nor postmortem interval explain the large variability observed in C1 amount. Interestingly, our results show that high levels of C1 are associated with the presence of the active ADAM 10 suggesting this zinc metalloprotease as a candidate for the cleavage of PrP(c) in the human brain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16263114     DOI: 10.1016/j.febslet.2005.10.013

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

1.  Effects of FlAsH/tetracysteine (TC) Tag on PrP proteolysis and PrPres formation by TC-scanning.

Authors:  Yuzuru Taguchi; Lindsay A Hohsfield; Jason R Hollister; Gerald S Baron
Journal:  Chembiochem       Date:  2013-08-13       Impact factor: 3.164

2.  The extracellular regulated kinase-1 (ERK1) controls regulated alpha-secretase-mediated processing, promoter transactivation, and mRNA levels of the cellular prion protein.

Authors:  Moustapha Cissé; Eric Duplan; Marie-Victoire Guillot-Sestier; Joaquim Rumigny; Charlotte Bauer; Gilles Pagès; Hans-Dieter Orzechowski; Barbara E Slack; Frédéric Checler; Bruno Vincent
Journal:  J Biol Chem       Date:  2011-05-17       Impact factor: 5.157

3.  Cellular prion protein regulates its own α-cleavage through ADAM8 in skeletal muscle.

Authors:  Jingjing Liang; Wei Wang; Debra Sorensen; Sarah Medina; Sergei Ilchenko; Janna Kiselar; Witold K Surewicz; Stephanie A Booth; Qingzhong Kong
Journal:  J Biol Chem       Date:  2012-03-23       Impact factor: 5.157

4.  Proteolytic processing of the prion protein in health and disease.

Authors:  Hermann C Altmeppen; Berta Puig; Frank Dohler; Dana K Thurm; Clemens Falker; Susanne Krasemann; Markus Glatzel
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

5.  Endogenous prion protein attenuates experimentally induced colitis.

Authors:  Gary R Martin; Catherine M Keenan; Keith A Sharkey; Frank R Jirik
Journal:  Am J Pathol       Date:  2011-09-13       Impact factor: 4.307

6.  A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation.

Authors:  Laura Westergard; Jessie A Turnbaugh; David A Harris
Journal:  J Biol Chem       Date:  2011-10-24       Impact factor: 5.157

Review 7.  Anchorless risk or released benefit? An updated view on the ADAM10-mediated shedding of the prion protein.

Authors:  Behnam Mohammadi; Feizhi Song; Andreu Matamoros-Angles; Mohsin Shafiq; Markus Damme; Berta Puig; Markus Glatzel; Hermann Clemens Altmeppen
Journal:  Cell Tissue Res       Date:  2022-01-27       Impact factor: 5.249

8.  Apparent reduction of ADAM10 in scrapie-infected cultured cells and in the brains of scrapie-infected rodents.

Authors:  Cao Chen; Yan Lv; Bao-Yun Zhang; Jin Zhang; Qi Shi; Jing Wang; Chan Tian; Chen Gao; Kang Xiao; Ke Ren; Wei Zhou; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2014-04-26       Impact factor: 5.590

9.  Separate mechanisms act concurrently to shed and release the prion protein from the cell.

Authors:  Lotta Wik; Mikael Klingeborn; Hanna Willander; Tommy Linne
Journal:  Prion       Date:  2012-10-23       Impact factor: 3.931

10.  Genetic predictions of prion disease susceptibility in carnivore species based on variability of the prion gene coding region.

Authors:  Paula Stewart; Lauren Campbell; Susan Skogtvedt; Karen A Griffin; Jon M Arnemo; Morten Tryland; Simon Girling; Michael W Miller; Michael A Tranulis; Wilfred Goldmann
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.